ACT-AD Comments to FDA on Its Proposed List of Disease Areas for FY 16-17 PFDD Meetings

ACT-AD submitted comments to the U.S. Food and Drug Administration on a proposed list of disease areas for patient-focused drug development meetings during fiscal years (FYs) 2016-2017. The patient-focused drug development meetings held to date covered aspects of diseases that are most important to those living with them and resulted in valuable publicly-available resources written in the voice of patients to help inform new endpoint development, outcome measure selection in clinical trials, and benefit/risk decision making by the FDA. ACT-AD’s comments urge the FDA to add Alzheimer’s disease to the list of nominated diseases and ask them to prioritize a meeting on Alzheimer’s disease in early FY 2016.
View Comments

File Attachments